Photocleavable Mass-Tags for Spatial Multiomics of Alzheimer’s Brain Tissue
用于阿尔茨海默病脑组织空间多组学的光裂解质量标签
基本信息
- 批准号:10684250
- 负责人:
- 金额:$ 108.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AD transgenic miceAddressAducanumabAffectAgarAlzheimer&aposs DiseaseAlzheimer&aposs disease brainAlzheimer&aposs disease pathologyAlzheimer&aposs disease therapyAmyloid beta-ProteinAntibodiesAutopsyBig DataBiological MarkersBiotechnologyBostonBrain DiseasesBrain imagingCholesterolChronicCollaborationsData AnalysesDementiaDiagnosticDrug TargetingEndosomesFDA approvedFluorescenceFourier transform ion cyclotron resonanceFunctional disorderGoalsHealth Care CostsHospitalsHumanImageImage AnalysisImaging TechniquesImaging technologyImmunohistochemistryLabelLectinLettersLinkLipidsMachine LearningMalignant neoplasm of prostateMapsMethodsModelingMolecularMolecular DiseaseMolecular TargetMonoclonal AntibodiesMultiomic DataMusMutationNeurodegenerative DisordersNeuronsPeptidesPersonsPharmaceutical PreparationsPharmacologic SubstancePhasePhospholipidsPhysicsPolysaccharidesProceduresProcessProductionProteinsPublic HealthResearchResearch PersonnelResolutionRoleSamplingSenile PlaquesSourceSpatial DistributionSpecimenSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationTissue imagingTissuesTransgenic MiceUncertaintyUniversitiesValidationWomanbrain tissuecohortcommercializationdesigndrug candidatehuman diseasehuman old age (65+)innovationinstrumentmalignant breast neoplasmmass spectrometric imagingmetermolecular imagingmolecular pathologymouse modelmultiple omicsnoveloperationpeptide drugpolypeptidepresenilin-1receptorsmall moleculetau Proteins
项目摘要
Summary/Abstract
Alzheimer's Disease (AD) is a chronic neurodegenerative disorder characterized by progressively worsening
dementia. AD currently affects over 6.2 million persons in the U.S. and approximately 30 million world-wide with
70% over the age of 65. The total public health cost of AD is expected to reach over $20 trillion by 2050. Despite
extensive efforts to develop AD therapies including small molecules, monoclonal antibodies and peptide-based
drugs, only aducanumab, whose efficacy is in doubt, has been approved by the FDA since 2004. A major challenge
is elucidating the molecular pathology involved in AD in order to develop effective early diagnostics and drugs.
While amyloid plaque formation due to aggregation of different Aβ-peptides has been an important focus, a myriad
of other molecules including tau, neuronal and glial receptors, endosomal-lysosomal related proteins, glycans,
phospholipids, cholesterol and metabolites have also been implicated in AD pathology. In order to obtain a detailed
understanding of the possible role of these diverse molecular species as well as the molecular targeting of candidate
drugs, there is an urgent need to develop sufficiently powerful, highly multiplexed and multiomic tissue imaging
techniques that can map at cellular resolution the 2D-spatial distribution and association of these diverse, AD
molecular players. The proposed Phase II project seeks to address this challenge by applying a new highly-
multiplexed, targeted method termed mass spectrometric imaging immunohistochemistry (MSI-IHC™). MSI-
IHC™ is based on the use of novel photocleavable mass-tags (PC-MTs) developed by AmberGen which when linked
to antibody or lectin probes enable targeted biomolecules to be identified in the mass spectrometric image. This
approach significantly exceeds the multiplex capability of fluorescence immunohistochemistry (IHC) and previous
cleavable mass-tag based methods which are generally limited to 5 biomarkers or require extensive cycling
procedures in the case of fluorescence. In addition, the ability to combine MSI-IHC™ with label-free, untargeted
small molecule mass spectrometric imaging (MSI) as well as fluorescence IHC imaging, on the same sample, greatly
extends its power. This is possible using unique double-labeled fluorescent-PC-MT probes and performing 2 rounds
of MSI. Together, these innovations can provide a much more comprehensive multiomic picture of the role of
various molecules in AD pathology. In Phase I, we have demonstrated the feasibility of this approach on mouse and
human brain tissue specimens including the ability to image simultaneously a variety of AD related molecules. In
Phase II we will build on this progress by applying MSI-IHC™ to human and transgenic AD mouse brain tissue
obtained from collaborators and commercial sources. One goal, in collaboration with Prof. R.A. Nixon at NYU, a
leading AD researcher, will be to investigate the role of neuronal endosomal dysfunction, the earliest known
pathobiology specific to AD. Image analysis with be performed using novel statistical physics and AI methods
previously developed for AD tissue and brain imaging.
摘要/摘要
阿尔茨海默病(AD)是一种以进行性恶化为特征的慢性神经退行性疾病
痴呆症。AD目前在美国影响着超过620万人,在全球范围内影响着大约3000万人
70%的人在65岁以上。预计到2050年,AD的公共卫生总成本将超过20万亿美元。尽管
广泛努力开发阿尔茨海默病治疗方法,包括小分子、单抗和多肽
自2004年以来,只有阿杜卡努单抗获得FDA批准,其疗效尚不确定。一项重大挑战
正在阐明阿尔茨海默病的分子病理学,以开发有效的早期诊断和药物。
而由于不同的Aβ多肽聚集而形成的淀粉样斑块一直是一个重要的焦点,无数的
其他分子包括tau,神经元和神经胶质受体,内体-溶酶体相关蛋白,多聚糖,
磷脂、胆固醇和代谢物也与AD的病理有关。为了获得一个详细的
了解这些不同分子物种的可能作用以及候选分子的靶向
药物,迫切需要发展足够强大、高度多元化和多组体的组织成像
可以在细胞分辨率下绘制这些不同AD的2D空间分布和关联的技术
分子玩家。拟议的第二阶段项目旨在通过应用新的高度-
多重、靶向的方法称为质谱学成像免疫组织化学(MSI-IHC™)。MSI-
IHC™是基于AmberGen公司开发的新型可光裂解质量标签(PC-MT)的使用,当连接到
抗体或凝集素探针使目标生物分子能够在质谱学图像中被识别。这
这种方法大大超过了荧光免疫组织化学(IHC)和以前的
基于可切割质量标签的方法,通常限于5个生物标志物或需要广泛的循环
在荧光情况下的程序。此外,将msi-ihc™与无标签、无靶向的
小分子质谱学成像(MSI)和荧光IHC成像,在同一样品上,大大
扩展了它的力量。这是可能的,使用独特的双标记荧光PC-MT探针和执行2轮
MSI的一部分。总而言之,这些创新可以提供一个更全面的多元化的角色图景
AD病理中的各种分子。在第一阶段,我们已经证明了这种方法在鼠标和
人脑组织标本包括同时成像多种AD相关分子的能力。在……里面
第二阶段,我们将在这一进展的基础上,将msi-ihc™应用于人和转基因AD小鼠的脑组织
从合作者和商业来源获得。一个目标是,与纽约大学的R.A.尼克松教授合作,
领先的AD研究人员将调查神经元内体功能障碍的作用,这是已知的最早
阿尔茨海默病特有的病理生物学。使用新的统计物理和人工智能方法进行图像分析
之前为AD组织和大脑成像开发的。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
MALDI HiPLEX-IHC: multiomic and multimodal imaging of targeted intact proteins in tissues.
- DOI:10.3389/fchem.2023.1182404
- 发表时间:2023
- 期刊:
- 影响因子:5.5
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark Lim其他文献
Mark Lim的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark Lim', 18)}}的其他基金
New Technology for High-Resolution Antibody Profiling for SARS-CoV-2
SARS-CoV-2 高分辨率抗体分析新技术
- 批准号:
10481680 - 财政年份:2022
- 资助金额:
$ 108.1万 - 项目类别:
A Highly Multiplexed, Multiomic 3D Mouse Brain Map Using MALDI-IHC
使用 MALDI-IHC 绘制高度多重、多组学 3D 小鼠脑图
- 批准号:
10603396 - 财政年份:2022
- 资助金额:
$ 108.1万 - 项目类别:
A Highly Multiplexed, Multiomic 3D Mouse Brain Map Using MALDI-IHC
使用 MALDI-IHC 绘制高度多重、多组学 3D 小鼠脑图
- 批准号:
10705203 - 财政年份:2022
- 资助金额:
$ 108.1万 - 项目类别:
New Technology for High-Resolution Antibody Profiling for SARS-CoV-2
SARS-CoV-2 高分辨率抗体分析新技术
- 批准号:
10686794 - 财政年份:2022
- 资助金额:
$ 108.1万 - 项目类别:
Photocleavable Mass-Tags for Spatial Multiomics of Alzheimer’s Brain Tissue
用于阿尔茨海默病脑组织空间多组学的光裂解质量标签
- 批准号:
10483988 - 财政年份:2022
- 资助金额:
$ 108.1万 - 项目类别:
Photocleavage Technology for Blood-based Multi-Biomarker Alzheimer's Disease Assay
用于基于血液的多生物标志物阿尔茨海默病检测的光裂解技术
- 批准号:
10227129 - 财政年份:2020
- 资助金额:
$ 108.1万 - 项目类别:
Highly Multiplexed Nanoscale Mass Spectrometric Imaging of Cancer Tissues
癌症组织的高度多重纳米级质谱成像
- 批准号:
9908822 - 财政年份:2018
- 资助金额:
$ 108.1万 - 项目类别:
Highly Multiplexed Nanoscale Mass Spectrometric Imaging of Cancer Tissues
癌症组织的高度多重纳米级质谱成像
- 批准号:
10019483 - 财政年份:2018
- 资助金额:
$ 108.1万 - 项目类别:
Photocleavage Technology for Improved Serum-based Multi-Biomarker Cancer Assays
用于改进基于血清的多生物标志物癌症检测的光裂解技术
- 批准号:
9175644 - 财政年份:2016
- 资助金额:
$ 108.1万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 108.1万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 108.1万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 108.1万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 108.1万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 108.1万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 108.1万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 108.1万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 108.1万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 108.1万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 108.1万 - 项目类别:
Research Grant